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Abstract
Introduction and Objective The potential of metamizole to cause drug-induced liver injury (DILI) has received increasing 
attention. We investigated the distinguishing features of a case series comprising 32 patients with suspected metamizole-
induced DILI.
Methods For the current analysis, 32 of 238 patients with DILI included in our prospective study on drugs potentially caus-
ing DILI were included. Diagnosis of DILI was based on expert opinion and RUCAM (Roussel Uclaf Causality Assessment 
Method) score and supported by an in vitro test using monocyte-derived hepatocyte-like cells.
Results Suspected metamizole-DILI was characterised by a female predominance, hepatocellular pattern of injury, high 
proportion of antinuclear antibody positivity, and predominance of eosinophilic cell infiltration and necrosis in the histo-
pathological analysis. With 22%, a high proportion of these metamizole-associated liver injury cases developed acute liver 
failure, which was characterised by a longer latency of metamizole use and more pronounced liver biochemistry abnormalities 
at onset and peak levels. Furthermore, jaundice was a common finding in the metamizole-associated liver injury cases with 
66% presenting with peak bilirubin levels of 3 mg/dL or higher, which was associated with a worse outcome and a higher 
frequency of acute liver failure.
Conclusions Our analysis of a well-characterised DILI cohort further supports the potential of metamizole causing DILI 
and provides important features for the establishment of a signature pattern of liver injury observed in patients treated with 
metamizole.
Clinical Trial Registration ClinicalTrials.gov: NCT 02353455.
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liver damage caused by metamizole have been published 
until recently [4]. In the drug label in Germany, neither the 
deterioration of liver function tests nor acute liver failure 
(ALF) is listed as an adverse event. Considering the exten-
sive hepatic metabolism of metamizole, mainly mediated 
by cytochrome P450 [5], its lipophilicity and the relatively 
high daily dose, all of which are known risk factors for drug-
induced liver injury (DILI) [6, 7], it is surprising that the 
hepatotoxic potential has not been a topic for pharmacovigi-
lance until now. Interestingly, Sebode et al. reported 23 cases 
of metamizole-induced DILI recently, which corresponded 
to 15% of all the DILI cases included in their centre [8]. The 
majority of the cases presented with a hepatocellular type 
of injury, nearly 50% of patients fulfilled Hy’s law criteria, 
meaning alanine aminotransferase (ALT) > 3 × the upper 
limit of normal (ULN) and total bilirubin (TBIL) > 2 × 
ULN, and 9% of the patients developed ALF [8].
Drug-induced liver injury is a diagnosis of exclusion, 
based on ruling out other causes for liver injury [9]. Because 
of the lack of specific biomarkers or diagnostic tests, 
1 Introduction
Metamizole is an analgetic, antipyretic and spasmolytic drug 
that was patented in Germany in 1922. It has been banned 
from the market in the USA and the UK because of its side 
effects, mainly severe agranulocytosis [1, 2]. However, it 
is still widely used in several countries and particularly 
in Germany the use has increased in recent years [3]. Yet, 
despite its use over several decades, only a few reports on 
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Key Points 
The analgetic drug metamizole was found to have 
probably caused drug-induced liver injury in 13% of all 
cases from our study cohort on suspected drug-induced 
acute liver injury, although other aetiologies including 
concomitantly administered products cannot be excluded 
as the cause of liver injury in some cases.
These metamizole-associated liver injuries are character-
ised by a hepatocellular type of injury, positive antinu-
clear antibodies, histopathological signs of inflammatory 
infiltrates with mainly eosinophilic cells as well as high 
proportions of moderate-to-severe necrosis.
A high proportion of patients with metamizole-asso-
ciated DILI developed acute liver failure. These cases 
of liver failure were characterised by a latency of 2–3 
months from metamizole intake to the onset of liver 
injury and high levels of transaminases, bilirubin and 
international normalised ratio both at onset and at 
respective peak levels.
Cholestatic forms of metamizole-associated DILI occur 
and are associated with a worse outcome.
prior to receiving therapy with drugs with DILI potential, 
patients with acute liver injury and DILI suspicion, as well 
as patients with acute liver injury as a result of other causes. 
Written informed consent was obtained from each patient. 
The study protocol conforms to the ethical guidelines of 
the Declaration of Helsinki and was approved by the Ethics 
Committee of the Faculty of Medicine, LMU Munich (pro-
ject number 55-13). For the current analysis, 32 patients who 
had consumed metamizole were selected.
2.2  Definition, Diagnosis and Classification of DILI
Acute liver injury was defined according to the consensus 
criteria from 2011: (a) ALT ≥ 5 × ULN, (b) alkaline phos-
phatase activity ≥ 2 × ULN, or (c) ALT ≥ 3 × ULN and 
TBIL ≥ 2 × ULN [12]. The ULN for aspartate aminotrans-
ferase (AST) activity and ALT were 35 U/L for women and 
50 U/L for men, the ULN for alkaline phosphatase was 
105 U/L for women and 130 U/L for men and the ULN for 
TBIL was 1.2 mg/dL. The type of liver injury was classified 
using the R ratio values, (ALT/ULN)/(alkaline phosphatase/
ULN), with R ≥5 defining a hepatocellular injury, R ≤ 2 
a cholestatic injury and 2 < R < 5 defining a mixed-type 
injury [13].
The diagnosis of DILI was based on clinical and lab-
oratory findings, the RUCAM score [14], a causality 
assessment by the treating physician and expert opinion 
[15], as well as an in vitro test established in our centre 
using monocyte-derived hepatocyte-like cells (MH cells) 
[16–18]. The interpretation of the RUCAM score is: < 0, 
drug is excluded as the cause; 1–2, unlikely; 3–5, possible; 
6–8, probable; and > 8, highly probable. Regarding the 
RUCAM score for metamizole, 1 point was given for the 
item ‘known hepatoxicity’, as liver injury is not listed as an 
adverse event in the drug label of metamizole but has been 
described in the literature [4, 8]. A causality assessment by 
the treating physician was conducted and expert opinion 
from consulting hepatologists from our centre was used 
by consideration of all clinical data available, the course 
of events and by using the LiverTox database [19]. The 
assessment of causality was performed independently from 
the MH cell test result.
Blood samples for MH cell testing were acquired within 
4 weeks after the onset of liver injury. Monocyte-derived 
hepatocyte-like cell generation and testing were performed 
as described previously [20]. Briefly, monocytes were iso-
lated from patients’ blood samples and cultivated under 
serum-free conditions for 10 days, generating cells with 
some hepatocyte features such as cytochrome P450 activi-
ties. These cells, MH cells, are incubated for 48 hours in 
96-well plates using 1 × maximum concentration (Cmax) 
and 10 × Cmax of the implicated drugs the respective 
patient had consumed. For the current analysis, MH cell 
adjudication of the culprit drug is based on causality assess-
ment scores, mainly the RUCAM (Roussel Uclaf Causality 
Assessment Method) score and expert opinion [6, 10]. How-
ever, relying on the RUCAM may not always be practical, as 
RUCAM comprises previously described DILI potential and 
reaction to re-exposure [11]. Thus, especially in the setting 
of polypharmacy, drugs that have formerly not been known 
to cause DILI will not be associated with liver injury, caus-
ing a bias towards underestimation of their potential to cause 
liver injury. To further investigate the role and features of 
metamizole in DILI, we analysed the clinical characteristics 
of patients with suspected metamizole-induced acute liver 
injury and compared the distinctive features of more severe 
metamizole-DILI cases.
2  Methods
2.1  Patient Cohort
The data from 383 patients who were referred to the 
University Hospital Munich with acute liver injury and 
recruited for our ongoing prospective study on the effects 
of potentially hepatotoxic drugs (ClinicalTrials.gov: NCT 
02353455) between March 2013 and July 2020 were ana-
lysed. Included in this study are healthy donors, patients 
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testing was performed for every patient and metamizole 
was tested in 94% of the patients included along with the 
concomitant medications used by the respective patients. 
Metamizole was used in concentrations of 50 µM and 500 
µM, which equals 1 × Cmax and 10 × Cmax of this drug. The 
lowest amount of cells used for a single test is 10,000 cells 
per well. All drugs are solved in a standardised medium 
(DMEM/HAM-F12 containing penicillin/streptomycin and 
2 l-glutamine). Then, toxicity is measured with a stand-
ardised algorithm based on the release of lactate dehy-
drogenase in the supernatant and cell lysate. Results are 
normalised to a negative (0%) and positive control (100%), 
meaning lysis with 1%  TWEEN®20 (polyethylene glycol 
sorbitan monolaurate). To compensate for variance in seed-
ing density, toxicity values are divided by two standard 
deviations (ULN) of the individual controls. The vector 
graphic demonstrating MH cell test results was created 
using Prism 8, Version 8.4.3.
The severity of the DILI episode was categorised as mild 
(1), moderate (2), severe (3) or fatal (4; death or the need 
for liver transplantation because of liver failure) according to 
the 2011 criteria of an international DILI expert group [12]. 
Acute liver failure was defined according to the American 
Association for the Study of Liver Diseases: (1) absence 
of pre-existing liver disease, (2) coagulopathy with an INR 
≥ 1.5 in the absence of oral anticoagulants and (3) hepatic 
encephalopathy [21]. ‘Hy’s law’ criteria were fulfilled if 
ALT was ≥ 3 × ULN and TBIL was ≥ 2 × ULN, defining a 
subgroup of patients with DILI with a 10% risk of fatality 
or need of liver transplantation [22].
2.3  Data Collection
At enrolment, a thorough medical history was taken, includ-
ing previous diseases, symptoms associated with liver injury, 
co-morbidities as well as current or previous medications. 
Each patient’s age, sex, ethnicity, height, weight and relevant 
data from clinical investigations were recorded. A thorough 
hepatological work-up, including liver function tests, sero-
logical studies for hepatitis A, B, C, D, and E, cytomegalo-
virus, Epstein–Barr virus and herpes simplex virus as well 
as autoantibody screening was performed, and results were 
extracted from the medical records. The presence of anti-
nuclear antibodies (ANA) and other liver-specific antibodies 
was tested using an indirect immunofluorescence assay kit, 
Mosaic Basic Profile 3 (Euroimmun, Lübeck, Germany). 
The immunofluorescence assay was performed with an 
initial dilution of 1:100. In addition to serological testing, 
hepatitis E polymerase chain reaction was performed in 50% 
of the cases. Whenever a liver biopsy was conducted during 
the diagnostic work-up, the results were extracted from the 
pathological report.
2.4  Statistical Analysis
Statistical analyses were performed using SPSS, Version 
26.0.0.1 (IBM, Armonk, NY, USA). After testing for normal 
distribution, parametric or non-parametric tests (Chi-square 
test, Fisher’s exact test or Mann–Whitney U test) were 
applied, p ≤ 0.05 was considered statistically significant.
3  Results
3.1  Clinical Characteristics and Outcome of Patients 
with Suspected Metamizole‑Induced DILI
From our cohort of 383 patients with acute liver injury who 
were included in our prospective study on potential DILI 
drugs owing to the initial suspicion of DILI, 238 patients 
were diagnosed with DILI. Out of those 238 patients, we 
identified 32 patients with suspected metamizole-induced 
DILI (13%). All of these patients had a concomitant medi-
cation: non-steroidal antirheumatic drugs were used in ten 
(31%) cases, antibiotics also in ten (31%) cases, anaesthetics 
in three (9%) cases, herbals in two (6%) cases and others in 
seven (22%) cases. For an overview of the concomitant med-
ication, see Table 1 of the Electronic Supplementary Mate-
rial (ESM). In all of the patients, RUCAM for metamizole 
was ≥ 3, meaning that metamizole was possibly, probably 
or highly probably the causative agent for the DILI episode. 
Adjudication by the treating physician revealed metamizole-
induced DILI as the most likely diagnosis in eight of the 
patients with DILI (25%), while in the remaining 24 patients 
(75%) an association with metamizole as the causative agent 
was assessed as the most likely diagnosis but could not be 
proven because of the intake of concomitant medication with 
a compatible time to onset. The clinical characteristics of the 
patients with suspected metamizole-induced DILI are sum-
marised in Table 1. Sixty-nine percent of the patients were 
female and the median age at diagnosis was 41 years. In the 
majority of cases, the patients presented with a hepatocel-
lular type of injury (n = 26, 81%). The median RUCAM 
score both for metamizole and the concomitant medication 
with the highest RUCAM was 5 (range 3–9). Anti-nuclear 
antibodies were found in 72% (n = 23) of the patients, 
while 34% (n = 11) presented with positive antimitochon-
drial antibodies (AMA). Median immunoglobulin G levels 
were within the range of normal (13.1 g/L [5.3–24.3 g/L]; 
ULN: 16 g/L), none of the patients were positive for other 
liver-specific autoantibodies, such as anti-smooth muscle 
antibodies, liver-kidney microsomal antibodies, or soluble 
liver antigen, and none of the patients had a persistent liver 
injury or relapse, ruling out autoimmune hepatitis or chronic 
autoimmune biliary disease. The median follow-up was 5 
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months, which ensured that relapse of liver injury did not 
occur after the acute episode of DILI.
Eight patients received corticosteroid treatment (25%), 
which was given at the discretion of the treating physician. 
Discontinuation of corticosteroids was possible in every 
patient. Most of the patients (n = 31, 94%) were in remission 
at the end of the follow-up, while two patients (6%) needed 
an emergency liver transplant because of ALF.
A liver biopsy was performed in 20 of the 32 patients 
(63%). The histopathological characteristics found in the 
liver specimen analysis are provided in Table 2 of the ESM. 
Inflammatory infiltrates were reported for every patient 
with a predominant infiltration with eosinophilic cells (n 
= 17, 85%). Further, in the majority of cases necrosis (n = 
17, 85%) of mostly moderate to pronounced intensity (n = 
12/17, 71%) was observed. Infiltration with plasma cells was 
found in 12 patients (60%). In four cases, a low-grade fibro-
sis was detected, while none of the patients presented with 
advanced fibrosis. Representative pictures of eosinophilic 
cell infiltration and necrosis in a liver biopsy from a patient 
with DILI from our cohort are shown in Fig. 1a–d. Seven 
patients had a positive re-challenge, meaning that they had 
a second episode of acute liver injury after unintentional 
re-exposure to metamizole alone (n = 3, 9%) or a combina-
tion of metamizole and the respective comedications (n = 
4, 13%). 
3.2  Subgroup Analysis: Comparison of Clinical 
and Histological Characteristics in Patients 
with Suspected Metamizole‑Induced Liver 
Injury in Relevance to a Causality Assessment 
Based on RUCAM Scoring
If patients with RUCAM ≥ 6 for metamizole (metamizole-
induced DILI probable or highly probable; n = 12) and 
RUCAM 3–5 (metamizole-induced DILI possible; n = 20) 
were compared, no significant differences regarding clini-
cal, laboratory and histopathological results were observed 
(Table 2). Age, sex distribution, the predominantly hepa-
tocellular type of injury, the level of liver function test 
abnormalities both at the onset of disease and at peak value, 
severity and outcome were similar between both groups. The 
only difference was that patients with RUCAM < 6 pre-
sented with higher rates of AMA positivity (45% vs 17%, p 
= 0.024). Histopathological analysis revealed that choles-
tasis was observed less often in patients with RUCAM ≥ 6 
for metamizole (10% vs 50%); however, this difference was 
not statistically significant (p = 0.051). Other histological 
patterns with moderately strong inflammatory infiltrates and 
moderate to pronounced necrosis were comparable between 
patients with RUCAM ≥ 6 and RUCAM < 6 (Table 3 of 
the ESM). A detailed overview of the characteristics of the 
individual patients with suspected metamizole-induced DILI 
cases and high RUCAM scores for metamizole is provided 
in Table 4 of the ESM.
3.3  Subgroup Analysis: Comparison of Clinical 
and Histological Characteristics in Patients 
with Suspected Metamizole‑Induced Liver 
Injury in Relevance to a Causality Assessment 
Based on MH Cell Test Results
Reliability of the RUCAM for a causality assessment is lim-
ited [11], especially in polymedicated patients. This is also 
illustrated in the current cohort: eight patients (25%) had a 
RUCAM of 6 or higher for both metamizole and at least one 
of the concomitant medications, while another six patients 
(19%) had RUCAM scores of 6 or higher for at least one of 
the concomitant drugs but not metamizole. In addition to 
expert opinion and RUCAM scoring as a gold standard for 
establishing the diagnosis, the causality assessment was sup-
ported by the MH cell test, an in vitro test system established 
Table 1  Clinical characteristics in patients with suspected metami-
zole-induced acute liver injury (n = 32)
Categorical variables are presented as number and percentage [n 
(%)]. Continuous variables are presented as median (range)
AMA antimitochondrial antibodies, ANA antinuclear antibodies, IgG 
immunoglobulin G, MH cell test monocyte-derived hepatocyte-like 
cell test, RUCAM Roussel Uclaf Causality Assessment Method, ULN 
upper limit of normal
a Some of the patients only took metamizole as needed and not on a 
regular daily basis. For those patients, the average daily dose accord-
ing to the weekly intake was calculated
b Aithal et al. Clin Pharmacol Ther. 2011;89(6):806–15
Age (years) 41 (19–79)
Body mass index (kg/m2) 23.3 (18.1–37.9)
Female sex 22 (69%)
RUCAM (metamizole) 5 (3–9)
Highest RUCAM (concomitant medication) 5 (3–9)
Latency metamizole (days) 42 (2–674)










IgG (g/L, ULN 16 g/L) 13.1 (5.3–24.3)
Severity according to Aithal et al.b 2 (1–4)
Corticosteroid treatment 8 (25%)
Acute liver failure 7 (22%)
Need for high-urgency liver transplantation 2 (6%)
Positive re-challenge with
 Metamizole
 Metamizole and concomitant medication
3 (9%)
4 (13%)
MH cell test positive for metamizole 24 (75%)
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in our centre and validated in patients with re-exposure 
previously [17]. The MH cell test was performed for every 
patient in this cohort and metamizole was tested for in 30/32 
(94%) of the cases. The MH cell test showed toxicity against 
metamizole in 24 of those 30 patients (75%). An overview of 
the individual test results for metamizole is shown in Fig. 1 
of the ESM. Patients with positive MH cell test results for 
metamizole were more likely to present with a hepatocel-
lular type of injury (88% vs 50%, p = 0.048). Otherwise, no 
significant differences were observed regarding clinical or 
laboratory characteristics (Table 3). Histopathological pat-
terns were also similar in patients who tested negative and 
positive for metamizole in the MH cell test (Table 3 of the 
ESM).
A special focus was placed on the 14 patients who pre-
sented with a RUCAM for the concomitant medication of 
at least 6. As stated above, eight of those patients also had 
a RUCAM for metamizole of 6 or higher. An overview over 
the individual patients’ MH cell test results for metamizole 
and the concomitant drugs is given in Table 5 of the ESM. 
Table 2  Comparison of clinical characteristics and outcome in patients with suspected metamizole-induced liver injury and RUCAM ≥ 6 vs 
RUCAM < 6 for metamizole
Categorical variables are presented as number and percentage [n (%)]. Continuous variables are presented as median (range). Laboratory values 
are presented as × ULN
ALP alkaline phosphatase, ALT alanine aminotransferase, AMA antimitochondrial antibodies, ANA antinuclear antibodies, AST aspartate ami-
notransferase, IgG immunoglobulin G, INR international normalised ratio, MELD Model of End Stage Liver Disease, MH cell test monocyte-
derived hepatocyte-like cell test, RUCAM Roussel Uclaf Causality Assessment Method, TBIL total bilirubin, ULN upper limit of normal
*Statistical significance (p ≤ 0.05)
a Some of the patients only took metamizole as needed and not on a regular daily basis. For those patients, the average daily dose according to the 
weekly intake was calculated
b Aithal et al. Clin Pharmacol Ther. 2011;89(6):806–15
RUCAM (metamizole) ≥ 6
n = 12 (37.5%)
RUCAM (metamizole) < 6
n = 20 (62.5%)
p value
Age (years) 55 (19–79) 38 (19–61) 0.17
Body mass index (kg/m2) 23.2 (18.1–30.6) 24.2 (18.9–37.9) 0.41
Female sex 10 (77%) 14 (61%) 0.56
Latency metamizole (days) 46 (2–370) 42 (8–674) 0.55












Peak ALT 29.8 (5.9–105.5) 45.3 (6.9–105.9) 0.17
Peak AST 12.5 (3.1–59.4) 35.4 (1.3–162.2) 0.08
Peak ALP 2.0 (1.0–7.8) 1.6 (1.0–4.3) 0.55
Peak TBIL 5.8 (0.7–27.9) 11.2 (0.5–29.9) 0.66
Peak INR 1.3 (0.9–6.6) 1.3 (0.9–8.0) 0.27
Peak MELD 14 (6–40) 20 (6–40) 0.27
IgG (g/L, ULN 16 g/L) 11.4 (5.3–17.6) 13.5 (7.0–24.3) 0.37
ANA positivity 11 (92%) 12 (60%) 0.054
AMA positivity 2 (17%) 9 (45%) 0.024*
Severity according to Aithal et al.b 2 (1–4) 2 (2–4) 0.92
Jaundice (TBIL >3 mg/dL) 8 (67%) 13 (65%) 0.92
Coagulopathy (INR >1.5) 4 (33%) 8 (40%) 0.71
Hy’s law criteria 9 (75%) 16 (80%) 0.74
Acute liver failure 2 (17%) 5 (25%) 0.58
Corticosteroid treatment 3 (25%) 5 (25%) 1.00
High-urgency liver transplantation 1 (8%) 1 (5%) 0.69
Re-exposure with
 Metamizole alone






MH cell test positive for metamizole 10 (83%) 14 (70%) 0.49
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The MH cell test results showed toxicity of metamizole but 
not of the comedication in seven (50%) cases and of a com-
bination of metamizole and the comedication in three (21%) 
cases. In four cases (29%), the MH cell test was negative for 
both metamizole and the co-administered drug.
In addition to testing patients with suspected metam-
izole-DILI, MH cell testing has also been performed on 
a variety of control subjects: (a) healthy controls (n = 
8), (b) patients with metamizole intake and acute liver 
injury caused by conditions other than DILI (n = 18), 
(c) patients with DILI without metamizole intake (n = 
17) and (d) patients with metamizole treatment but DILI 
due to another drug (n = 39). Regarding the healthy con-
trols, half had been exposed to metamizole (n = 4). The 
test was negative in seven of all eight healthy controls 
(88%) and three of the four (75%) healthy controls with 
prior metamizole intake. In 15 out of the 18 patients with 
intake of metamizole but liver injury not associated with 
DILI, the test showed negative results (83%). Regarding 
DILI patients without a prior intake of metamizole, MH 
cell testing yielded negative results in 34/39 cases (87%). 
In patients with DILI with prior metamizole therapy but 
in whom liver injury was highly likely associated with 
another drug (n = 17), the MH cell test gave negative 
results in 16 cases (94%). Positive results for the concom-
itant medication were observed in 16 of those 17 patients. 
One case had a positive result for both metamizole and 
the concomitant herbal drug and in one case the MH cell 
test was negative for both metamizole and the concomi-
tant medication.
3.4  Subgroup Analysis: Comparison of Clinical 
and Histological Characteristics in Patients 
with Suspected Metamizole‑Induced Liver 
Injury According to Jaundice
To focus on the more distinctive features of severe cases 
among all of the 32 cases of suspected metamizole-induced 
DILI, a subgroup analysis was performed comparing patients 
with DILI who developed a clinically relevant jaundice, i.e., 
peak TBIL >3 mg/dL, with patients without clinically rel-
evant jaundice (Table 4). Regarding the basic clinical param-
eters, jaundiced patients with DILI-developed liver injury 
with a longer latency from the start of metamizole intake 
(58 vs 31 days, p = 0.039) presented with higher peak lev-
els of ALT, AST, TBIL and INR, as well as higher MELD 
scores both at the onset of liver injury and at peak levels. 
Severity according to the 2011 criteria [12] was significantly 
higher in jaundiced patients (severe [3] vs moderate [1], p 
= 0.002). Moreover, coagulopathy as well as Hy’s law posi-
tivity was observed more often in jaundiced patients. This 
also translated into a higher occurrence of ALF, which was 
observed in 33% of the jaundiced patients but for none of 
the non-jaundiced patients (p = 0.03). Two of the jaundiced 
patients required high-urgency liver transplantation (10% vs 
0%, p = 0.23). A liver biopsy was performed in the majority 
of patients with jaundice (n = 15, 71%), and in 46% of the 
patients without jaundice (n = 5; Table 6 of the ESM). Inter-
estingly, the proportion of patients presenting with steatosis 
was significantly higher in non-jaundiced patients (60% vs 
7%, p = 0.034) while cholestasis (mainly hepatocellular and 
Fig. 1  Histology of liver biopsy. 
Liver biopsy revealed moderate 
portal and lobular hepatitis with 
liver cell drop out, confluent 
necrosis and mild fibrosis (a, 
haematoxylin and eosin stain, 
25-fold). In a larger magnifica-
tion (b, haematoxylin and eosin 
stain, 100-fold), lymphohistio-
cytic infiltrates with scattered 
eosinophils and apoptosis of 
liver cells could be obtained. 
In c (haematoxylin and eosin 
stain, 200-fold), aggregated 
eosinophil granulocytes and 
in d (haematoxylin and eosin 
stain, 200-fold) apoptotic bod-
ies (‘Councilman bodies’) are 
shown
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canalicular) and fibrosis were only observed in liver speci-
mens of jaundiced patients (40% vs 0%, p = 0.09; and 27% 
vs 0%, p = 0.20, respectively).
3.5  Subgroup Analysis: Subgroup Analysis 
of Patients with ALF
Seven of the 32 patients (22%) with suspected metam-
izole-induced DILI presented with ALF. Concomitant 
medications used by these patients were ibuprofen (n = 4), 
cefuroxime (n = 4), sevoflurane (n = 3), propofol (n = 2), 
diclofenac (n = 2), acetylsalicylic acid, amoxicillin/clavu-
lanic acid, ampicillin/sulbactam, ciprofloxacin, dienogest/
ethinylestradiol, pantoprazole, paracetamol, valsartan and 
zopiclone (each n = 1). Patients who developed ALF had 
a longer latency between the initiation of metamizole and 
the onset of liver injury (80 vs 34 days, p = 0.033) and 
higher levels of AST, TBIL, INR and MELD both at the 
onset of liver injury and at the respective peak levels as 
well as higher ALT levels at onset (Table 5). Patients with 
ALF also had a higher severity according to the 2011 cri-
teria [12] and were more likely to present with jaundice or 
coagulopathy, while there was no significant difference in 
Hy’s law positivity (Table 5). In accordance with the higher 
severity of those cases, the proportion of patients needing 
high-urgency liver transplantation was also significantly 
Table 3  Comparison of clinical 
and laboratory features in 
patients with DILI and the 
intake of metamizole and 
positive or negative MH cell test 
results for metamizole
MH cell test results for metamizole were available for 30 (94%) patients. Categorical variables are pre-
sented as number and percentage of the respective group size [n (%)]. Continuous variables are presented 
as median (range). Laboratory values are presented as × ULN
ALP alkaline phosphatase, ALT alanine aminotransferase, AST aspartate aminotransferase, DILI drug-
induced liver injury, INR international normalised ratio, MELD Model of End Stage Liver Disease, MH 
cell test monocyte-derived hepatocyte-like cell test, RUCAM Roussel Uclaf Causality Assessment Method, 
TBIL total bilirubin, ULN upper limit of normal
*Statistical significance (p ≤ 0.05)
a Some of the patients only took metamizole as needed and not on a regular daily basis. For those patients, 
the average daily dose according to the weekly intake was calculated
b Aithal et al. Clin Pharmacol Ther. 2011;89(6):806–15
Positive MH cell test 
for metamizole
n = 24 (75%)
Negative MH cell test 
for metamizole
n = 6 (25%)
p value
Age (years) 39 (19–64) 45 (34–79) 0.40
Body mass index (kg/m2) 23.2 (17.6–37.9) 24.1 (18.1–25.9) 0.81
Female sex 17 (71%) 4 (67%) 0.84
RUCAM (metamizole) 5 (3–9) 5 (4–7) 0.49
Highest RUCAM (concomitant medication) 5 (3–9) 6 (5–6) 0.53
Latency metamizole (days) 46 (2–674) 41 (15–82) 0.64












Severity according to Aithal et al.b 2 (1–4) 2 (2–3) 0.40
Peak ALT 37.4 (5.9–105.5) 24.1 (7.6–105.9) 0.43
Peak AST 29.2 (3.1–162.2) 18.1 (1.3–69.4) 0.49
Peak ALP 1.7 (1.0–4.3) 2.1 (1.0–7.8) 0.40
Peak TBIL 5.8 (0.5–29.9) 6.0 (0.8–23.1) 0.71
Peak INR 1.3 (0.9–8.0) 1.2 (0.9–1.7) 0.33
MELD at onset of liver injury 12 (6–30) 12 (6–24) 0.72
Peak MELD 14 (6-40) 15 (6–24) 0.89
Jaundice (TBIL > 3 mg/dL) 15 (63%) 4 (67%) 0.85
Coagulopathy (INR > 1.5) 9 (38%) 1 (17%) 0.33
Hy’s law criteria 18 (75%) 5 (83%) 0.67
Acute liver failure 5 (21%) 1 (17%) 0.82
Corticosteroid treatment 6 (25%) 2 (33%) 0.68
High-urgency liver transplantation 2 (8%) 0 (0%) 0.66
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higher (29% vs 0%, p = 0.02). Regarding histopathological 
analysis, patients with ALF more frequently presented with 
mild fibrosis (60% vs 7%, p = 0.01), while the patients who 
did not develop ALF showed a higher proportion of eosino-
philic cell infiltration (93% vs 60%, p = 0.033; Table 6 of 
the ESM).
4  Discussion
In our cohort of 238 patients with DILI, 32 patients (13 %) 
were diagnosed with suspected metamizole-induced liver 
injury. This proportion is in line with the results recently 
published by Sebode et al., who reported that metamizole 
Table 4  Comparison of clinical characteristics and outcome in patients with suspected metamizole-induced liver according to the development 
of jaundice
Categorical variables are presented as number and percentage [n (%)]. Continuous variables are presented as median (range). Laboratory values 
are presented as × ULN
ALP alkaline phosphatase, ALT alanine aminotransferase, AST aspartate aminotransferase, INR international normalised ratio, IgG immuno-
globulin G, MELD Model of End Stage Liver Disease, RUCAM Roussel Uclaf Causality Assessment Method, TBIL total bilirubin, ULN upper 
limit of normal
*Statistical significance (p ≤ 0.05)
a Some of the patients only took metamizole as needed and not on a regular daily basis. For those patients, the average daily dose according to the 
weekly intake was calculated
b Aithal et al. Clin Pharmacol Ther. 2011;89(6):806–15
Jaundiced patients 
(TBILpeak > 3 mg/dL)
n = 21 (66%)
Non-jaundiced patients 
(TBILpeak ≤ 3 mg/dL)
n = 11 (34%)
p value
Age (years) 34 (19–79) 53 (28–61) 0.10
Body mass index (kg/m2) 23.7 (18.1–37.9) 22.9 (19.1–30.6) 0.49
Female sex 16 (70%) 8 (62%) 0.62
RUCAM (metamizole) 5 (3–8) 5 (3–9) 0.79
Highest RUCAM (concomitant medication) 6 (3–9) 5 (4–8) 0.46
Latency metamizole (days) 58 (2–674) 31 (2–55) 0.039*












Peak ALT 47.5 (5.9–105.9) 27.1 (6.9–62.0) 0.009*
Peak AST 38.1 (3.1–104.0) 11.4 (1.3–162.2) 0.008*
Peak ALP 1.8 (1.0–7.8) 1.6 (1.0–2.5) 0.10
Peak TBIL 19.8 (2.6–29.9) 0.8 (0.5–2.8) 0.000*
Peak INR 1.5 (0.9–8) 1.0 (0.9–1.3) 0.000*
ALT onset 42.5 (3.8–105.5) 27.1 (6.9–62.0) 0.07
AST onset 33.9 (2.5–104.0) 10.5 (1.1–32.3) 0.001*
ALP onset 1.6 (0.9–5.8) 1.5 (0.6–2.5) 0.10
TBIL onset 12.7 (0.2–22.1) 0.7 (0.4–2.1) 0.000*
Severity according to Aithal et al.b 3 (2–4) 2 (1–2) 0.002*
Jaundice at onset of liver injury (TBIL > 3 mg/dL) 17 (81%) 0 (0%) 0.000*
MELD at onset of liver injury 21 (6–40) 6 (6–10) 0.000*
Peak MELD 23 (10–40) 6 (6–13) 0.000*
Time from onset until peak MELD (days) 4 (0–21) 0 (0–77) 0.20
Time from onset until peak ALT 4 (0–99) 0 (0–10) 0.012*
Time from onset until peak TBIL (days) 8 (0–99) 4 (0–77) 0.06
Coagulopathy (INR > 1.5) 12 (57%) 0 (0%) 0.002*
Hy’s law criteria 21 (100%) 4 (36%) 0.000*
Acute liver failure 7 (33%) 0 (0%) 0.03*
Corticosteroid treatment 7 (33%) 1 (9%) 0.13
High-urgency liver transplantation 2 (10%) 0 (0%) 0.23
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was the implicated drug in 15% of their DILI cases [8]. 
The relatively high percentage of patients using metami-
zole in our cohort and their DILI cohort can be explained 
by the growing popularity of metamizole as an analgetic 
in the German market [3], which emphasises the need to 
further investigate its potential to cause DILI. In clinical 
trials, the potential of certain drugs to cause liver injury 
can be missed owing to the low incidence of overt DILI and 
therefore might only be revealed by post-marketing surveil-
lance studies or voluntary reporting of suspected cases of 
liver injury [23, 24]. A DILI diagnosis and causality assess-
ment is challenging, especially in the case of polymedication 
because no reliable diagnostic test is available. Physicians 
need to rely on expert opinion and causality assessment 
tools like the RUCAM score. However, the RUCAM score 
might be misleading as it comprises previous information on 
hepatotoxicity and reaction to re-exposure of the implicated 
drug, which limits its efficacy in evaluating agent-causing 
liver injury in clinical trials and for drugs commonly not 
associated with DILI [25]. Thus, the DILI potential of drugs 
that have not been related to DILI neither in clinical trials 
nor post-marketing, such as metamizole, can be underes-
timated. In line with this, only 38% of the patients in our 
cohort presented with a RUCAM score for metamizole of 6 
or higher while the RUCAM score for the comedication was 
6 or above in 14 (44%) cases. We therefore sought to analyse 
the characteristics of patients with suspected metamizole-
DILI to establish a more profound clinical and pathological 
signature of metamizole-DILI.
Table 5  Characteristics 
of patients with suspected 
metamizole-induced liver injury 
with and without acute liver 
failure
Categorical variables are presented as number and percentage [n (%)]. Continuous variables are presented 
as median (range). Laboratory values are presented as × ULN
ALP alkaline phosphatase, ALT alanine aminotransferase, AST aspartate aminotransferase, INR inter-
national normalised ratio, MELD Model of End Stage Liver Disease, RUCAM Roussel Uclaf Causality 
Assessment Method, TBIL total bilirubin, ULN upper limit of normal
*Statistical significance (p ≤ 0.05)
a Some of the patients only took metamizole as needed and not on a regular daily basis. For those patients, 
the average daily dose according to the weekly intake was calculated
b Aithal et al. Clin Pharmacol Ther. 2011;89(6):806–15
Acute liver failure
n = 7 (22%)
No acute liver failure
n = 25 (78%)
p value
Age (years) 35 (26–64) 43 (19–79) 0.76
Body mass index (kg/m2) 24.2 (18.1–28.3) 23.3 (18.9–37.9) 0.66
Female sex 4 (57%) 18 (72%) 0.45
Latency metamizole (days) 80 (27–674) 34 (2–370) 0.033*
Daily dosage metamizole (mg)a 1000 (1000–1500) 1500 (71–4000) 0.61
RUCAM score for metamizole 5 (3–8) 5 (3–9) 0.82
Maximum RUCAM score for concomi-
tant medication
6 (3–9) 5 (4–8) 0.66












Peak ALT 60.5 (14.9–100.0) 33.2 (5.9–105.9) 0.09
Peak AST 50.9 (22.5–104.0) 18.9 (1.3–162.2) 0.004*
Peak ALP 1.9 (1.3–3.4) 1.7 (1.0–7.8) 0.40
Peak TBIL 24.1 (20.7–29.9) 4.2 (0.5–23.1) 0.000*
Peak INR 2.2 (1.7–8.0) 1.2 (0.8–2.1) 0.000*
MELD at onset of liver injury 25 (20–30) 9 (6–26) 0.000*
Peak MELD 26 (23-40) 13 (6–26) 0.000*
Severity according to Aithal et al.b 3 (3–4) 2 (1–3) 0.000*
Jaundice (TBIL > 3 mg/dL) 7 (100%) 14 (56%) 0.03*
Coagulopathy (INR > 1.5) 7 (100%) 5 (20%) 0.000*
Hy’s law criteria 7 (100%) 18 (72%) 0.11
Corticosteroid treatment 2 (29%) 6 (24%) 0.81
High-urgency liver transplantation 2 (29%) 0 (0%) 0.02*
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Clinical characteristics with a slight female predom-
inance, a median age at onset of 41 years as well as the 
mostly hepatocellular pattern of injury were comparable to 
those in patients with metamizole-DILI described recently 
[8]. Interestingly, it could be shown by thoroughly analysing 
histopathological features that a relatively large proportion 
of patients presented with necrosis and eosinophilic cell 
infiltration (85% respectively).
To identify possible distinguishing features for the 
effectiveness of causality assessment tools in metamizole-
induced DILI, we performed a subgroup analysis compar-
ing the clinical and histopathological characteristics in 
patients with probable or highly probably metamizole-DILI 
(RUCAM ≥6) and possible metamizole-DILI (RUCAM 
3–5). While ANA positivity was quite a frequent finding 
in all patients, lower RUCAM scores correlated with AMA 
positivity. The finding of relatively high ANA and AMA 
positivity is in line with recent data from our group dem-
onstrating that ANA and also AMA positivity is frequently 
found in patients with DILI [26]. Furthermore, cholestasis 
was a prominent feature in the histopathological analysis 
in patients with higher RUCAM scores; however, this dif-
ference did not reach statistical difference. Apart from this, 
no other relevant differences between patients with higher 
and lower RUCAM scores were identified. In conclusion, 
the current results indicate that both patients with RUCAM 
≥ 6 or < 6 were fairly similar, which argues against the 
RUCAM score being a reliable discriminating tool in the 
assessment of metamizole-induced DILI. Thus, in addition 
to RUCAM, a causality assessment should be based on a 
variety of methods, for example, expert opinion, evolution of 
liver parameters after discontinuation of the drug, potential 
re-exposure and possibly a causality assessment toll such as 
MH cell testing. Especially in the case of metamizole, evalu-
ating re-challenges could be useful, as metamizole might be 
prescribed again even after an episode of DILI because of 
the underestimation of its DILI potential. In line with this, 
seven out of the 32 patients from our cohort (22%) reported a 
mostly unintentional positive re-challenge with metamizole.
Strikingly, a high proportion of patients developed not 
only jaundice (66%) but also ALF (22%). When focusing on 
the distinctive features of more severe metamizole-induced 
DILI cases, the development of clinically relevant jaundice 
was associated with higher serum transaminases and INR 
levels at onset and at peak levels, longer latency from the 
initiation of metamizole treatment, and a more pronounced 
cholestasis and higher frequency of fibrosis in the histo-
pathological analysis. Jaundiced patients were also more 
likely to have a more unfavourable outcome with higher pro-
portions of patients developing ALF. Thus, a more severe 
evolution and possibly the development of ALF needs to 
be expected in the case of a latency of approximately 2–3 
months from the initiation of metamizole intake as well as 
severely altered serum liver biochemistry.
Because metamizole has been underestimated as a causa-
tive agent in DILI, little is known about the mechanisms of 
metamizole-induced liver injury. The current understanding 
of idiosyncratic DILI is that the adaptive immune system 
plays an important role in the pathogenesis of the liver injury 
[6, 27]. The characteristics observed in the patients with sus-
pected metamizole-DILI, i.e., immune cell infiltration in all 
of the liver specimens with a predominance of eosinophilic 
cells as well as a high percentage of ANA positivity, indicate 
that immunological mechanisms might also play a pivotal 
role in metamizole-induced liver injury. This is in line with 
scarce previous data on metamizole-DILI proposing a poten-
tial immune-mediated mechanism [28].
Our results have major implications for clinical trials 
as well as post-marketing pharmacovigilance. It could be 
demonstrated in our cohort that metamizole-induced liver 
injury needed to be suspected in 13% of all patients with 
DILI. Especially in Germany, the use of metamizole has 
further increased in recent years [3], which might lead to 
an increase in metamizole-induced DILI cases as well. As 
metamizole is often taken as a concomitant analgetic medi-
cation in polymedicated patients and might also be used by 
patients participating in clinical trials, it can possibly cause 
liver injury unrelated to the study medication or other impor-
tant treatments that cannot easily be replaced by alternative 
drugs. Because DILI is one of the major reasons for the ces-
sation of drug development and post-marketing withdrawals 
[6, 9], an adequate causality assessment is therefore crucial 
to avoid unnecessary project terminations [25]. Thus, we 
encourage physicians treating patients with suspected DILI 
as well as clinical investigators to consider metamizole as a 
DILI-causing agent and actively ask the patient about con-
comitant metamizole use.
Our study has limitations, for instance, the lack of a uni-
versal gold standard for the causality assessment. For the 
current analysis, the DILI diagnosis and causality assess-
ment were based on expert opinion and RUCAM scoring 
and were supported by MH cell testing. However, the use-
fulness of the RUCAM score is limited, as the RUCAM 
comprises the existing knowledge about the DILI potential 
of the respective drug. As neither ALF nor elevation of liver 
function tests is listed in the labelling of metamizole, an 
underestimation of the actual RUCAM might be possible. 
In addition, all of the patients had concomitant medications, 
mainly antibiotics and non-steroidal antirheumatic drugs, 
which were used in half of the cases. It cannot be fully 
excluded that the liver injury was caused by the concomi-
tant medication taken by the patients from our cohort. Yet, 
there is a potential bias, especially regarding the causality 
assessment based on RUCAM, as liver injury is listed as 
an adverse reaction in the drug labels of most antibiotics 
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and analgesics, which automatically increases the RUCAM 
score for the majority of the comedications. In line with 
this, the median RUCAM score for metamizole and for the 
concomitant drug with the highest RUCAM was 5, which 
shows that the RUCAM score cannot reliably discriminate 
metamizole among other possible causative agents of DILI 
in polymedicated patients. Therefore, we would like to sug-
gest a score of two rather than one in the RUCAM score 
for metamizole for the item known hepatoxicity. This would 
automatically lead to higher RUCAM scores and therefore 
less underestimation of metamizole in DILI. If a score of two 
for known potential to cause DILI was assumed for meta-
mizole, median RUCAM would have been 6 (4–10) in our 
cohort with 21 patients (66%) reaching a RUCAM of 6 or 
higher and 18 of those (85%) presenting with positive MH 
cell test results for metamizole.
A unique strength of our study is the use of an in vitro test 
system. While in the work of Sebode et al. the DILI diagno-
sis and causality assessment were solely based on RUCAM 
scoring [8], in the current analysis, diagnosis was supported 
by the MH cell test, which can help to identify the causative 
drug especially in the setting of comedications. The MH cell 
test showed positive results for metamizole in more than 80% 
of patients with a RUCAM for metamizole of 6 or higher and 
was positive for metamizole in 70% of the DILI cases with a 
RUCAM of 3–5 for metamizole. Thus, while a DILI diagno-
sis and causality assessment solely based on RUCAM may 
lead to an under- or overestimation of metamizole-DILI, our 
results including a causality assessment tool further support 
the role of metamizole as a causative agent in patients with 
DILI. However, while the MH cell test has been validated in 
a cohort of patients with positive re-challenge to the respec-
tive medication with high sensitivity and specificity [17], 
external validation has not been completed yet. Thus, the 
reliability of the MH cell tests as a causality assessment tool 
needs further assessment. To minimise the overestimation of 
metamizole-induced DILI by the MH cell test, a variety of 
control subjects who have been tested with this assay were 
included (healthy subjects, patients with metamizole intake 
but liver injury of an alternative cause, patients with DILI 
without prior metamizole treatment and patients with DILI 
with prior metamizole but association with a different drug). 
With the application of results from this collection of sam-
ples, the MH cell test would rule out metamizole-induced 
liver injury with a specificity of 83–94%.
5  Conclusions
The identification of 32 patients with suspected metam-
izole-associated DILI in our cohort of patients with liver 
injury further underlines the DILI potential of metamizole. 
Based on our results, the signature of this injury includes a 
hepatocellular pattern, a high proportion of ANA positiv-
ity with also a quite frequent positivity for AMA, and high 
proportions of inflammatory infiltrates with a predominance 
of eosinophilic cells and high rates of moderate-to-strong 
necrosis. A considerable proportion of patients developed 
jaundice and ALF.
We therefore propose that metamizole should be regarded 
as a possibly causative agent in DILI, especially in patients 
with the above-described clinical and histopathological fea-
tures. The possible causal relationship of metamizole and 
DILI should also create more awareness among physicians 
taking the history of previous medications as well as inves-
tigators in clinical trials or pharmacovigilance reports. As a 
future perspective, this could lead to less under-reporting of 
concomitant use of metamizole by the patient and therefore 
to a more appropriate consideration of its role in causing 
DILI.
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